|
End-of-day quote
Euronext Paris
2024-02-05
|
5-day change | 1st Jan Change | ||
| 1.980 EUR | -1.00% |
|
-1.00% | -1.00% |
| 06-30 | Neovacs bolsters its strategic intellectual property portfolio |  |
| 02-10 | Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted | CI |
Company Valuation: NEOVACS
Data adjusted to current consolidation scope
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Market Cap 1 | - | - | - | - | - | - |
| Change | - | - | - | - | - | - |
| Enterprise Value (EV) 1 | - | - | - | - | - | - |
| Change | - | - | - | - | - | - |
| P/E | -96,912,987x | -264,999,452x | -6,728x | -22,860,253x | - | - |
| PBR | - | - | - | - | - | - |
| PEG | - | 3,273,301.5x | -0x | 229,169x | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / EBIT | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.0479 | -0.009117 | -5.946 | -0.0147 | - | - |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 0.0952 | 0.031 | 0.0225 | 0.001112 | 0.5334 | 0.4339 |
| EBITDA 1 | -8.118 | -3.437 | -7.728 | -6.294 | -6.06 | -6.43 |
| EBIT 1 | -8.175 | -3.492 | -7.828 | -6.445 | -6.908 | -6.622 |
| Net income 1 | -7.548 | -6.143 | -11.84 | -3.549 | -8.743 | -32.91 |
| Net Debt 1 | -1.234 | -9.681 | -32.06 | -5.555 | -0.2365 | -0.2051 |
| Reference price 2 | 4,640,000.0000 | 2,416,000.0000 | 40,000.0000 | 336,000.0000 | 20,000.0000 | 10,212,000.0000 |
| Nbr of stocks (in thousands) | - | - | - | - | - | - |
| Announcement Date | 4/30/20 | 6/29/21 | 5/2/22 | 4/30/23 | 4/30/24 | 4/30/25 |
1EUR in Million2EUR
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.76x | 5.88x | 17.63x | 0.99% | 48.41B | |
| -21.5x | 245.64x | -23.19x | -.--% | 45.01B | |
| 34.48x | 3.33x | 14.35x | -.--% | 44.07B | |
| 46.93x | 5.43x | 29.72x | -.--% | 40.73B | |
| 28.26x | 8.5x | 21.55x | 0.4% | 33.21B | |
| 33.62x | 5.51x | 25.02x | -.--% | 16.5B | |
| 23.87x | 2.08x | 9x | 1.13% | 14.45B | |
| 77.18x | 4.06x | 15.75x | -.--% | 13.77B | |
| Average | 31.95x | 35.05x | 13.73x | 0.32% | 32.02B | |
| Weighted average by Cap. | 27.13x | 47.50x | 12.21x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALNEV Stock
- ALNEV Stock
- Valuation NEOVACS
Select your edition
All financial news and data tailored to specific country editions
